Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Fulcrum Therapeutics, retaining the price target of $12.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Fein’s rating is based on the promising preclinical data presented by Fulcrum Therapeutics for their EED inhibitor, FTX-6274, in treating castration-resistant prostate cancer (CRPC). The compound has demonstrated significant tumor growth inhibition and extended survival in preclinical models, suggesting strong potential for future clinical success.
Additionally, the advancement of FTX-6274 into solid tumor indications represents a strategic expansion for Fulcrum beyond its traditional focus, which could enhance the company’s long-term growth prospects. The continued progress of Fulcrum’s lead asset, pociredir, in sickle cell disease, further supports the company’s valuation, providing a solid foundation complemented by a growing pipeline. These factors collectively underpin Fein’s Buy rating and the $12 price target for Fulcrum Therapeutics.
According to TipRanks, Fein is a 5-star analyst with an average return of 26.0% and a 53.25% success rate. Fein covers the Healthcare sector, focusing on stocks such as Alector, BioCryst, and United Therapeutics.
In another report released on October 8, Leerink Partners also reiterated a Buy rating on the stock with a $16.00 price target.